Immunohistochemically detected IDH1 R132H mutation is rare and mostly heterogeneous in prostate cancer

摘要

Background IDH1 mutations are oncogenic through induction of DNA damage and genome instability. They are of therapeutic interest because they confer increased sensitivity to radiation and cytotoxic therapy and hold potential for vaccination therapy. Methods In this study, we analyzed more than 17,000 primary prostate cancer tissues with a mutation-specific antibody for the IDH1_(R132H)mutation. Results IDH1 mutation-specific staining was found in 42 of 15,531 (0.3%) interpretable cancers. IDH1 mutation was associated with higher preoperative PSA and Gleason grade ( p ?